Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2015 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Modes of resistance to anti-angiogenic therapy.
Bergers G, Hanahan D. Bergers G, et al. Nat Rev Cancer. 2008 Aug;8(8):592-603. doi: 10.1038/nrc2442. Nat Rev Cancer. 2008. PMID: 18650835 Free PMC article. Review.
Intertwined regulation of angiogenesis and immunity by myeloid cells.
Rivera LB, Bergers G. Rivera LB, et al. Trends Immunol. 2015 Apr;36(4):240-9. doi: 10.1016/j.it.2015.02.005. Epub 2015 Mar 11. Trends Immunol. 2015. PMID: 25770923 Free PMC article. Review.
The role of pericytes in blood-vessel formation and maintenance.
Bergers G, Song S. Bergers G, et al. Neuro Oncol. 2005 Oct;7(4):452-64. doi: 10.1215/S1152851705000232. Neuro Oncol. 2005. PMID: 16212810 Free PMC article. Review.
Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Rivera LB, et al. Cell Rep. 2015 Apr 28;11(4):577-91. doi: 10.1016/j.celrep.2015.03.055. Epub 2015 Apr 16. Cell Rep. 2015. PMID: 25892230 Free PMC article.
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. Lu KV, et al. Cancer Cell. 2012 Jul 10;22(1):21-35. doi: 10.1016/j.ccr.2012.05.037. Cancer Cell. 2012. PMID: 22789536 Free PMC article.
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Jahangiri A, et al. Clin Cancer Res. 2013 Apr 1;19(7):1773-83. doi: 10.1158/1078-0432.CCR-12-1281. Epub 2013 Jan 10. Clin Cancer Res. 2013. PMID: 23307858 Free PMC article.
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.
Ishida S, McCormick F, Smith-McCune K, Hanahan D. Ishida S, et al. Cancer Cell. 2010 Jun 15;17(6):574-83. doi: 10.1016/j.ccr.2010.04.011. Cancer Cell. 2010. PMID: 20541702 Free PMC article.
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Pàez-Ribes M, et al. Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027. Cancer Cell. 2009. PMID: 19249680 Free PMC article.
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E, Walters IB, Hanahan D. Allen E, et al. Clin Cancer Res. 2011 Aug 15;17(16):5299-310. doi: 10.1158/1078-0432.CCR-10-2847. Epub 2011 May 27. Clin Cancer Res. 2011. PMID: 21622725 Free PMC article.
Feedback